Abstract:A diverse collection of myeloid disorders known as myelodysplastic syndromes (MDS) arise from progenitor or stem cells and contributed to the existence of clonal hematopoiesis. Numerous mutations in genes of stem cell during MDS development affect their proliferation and differentiation. This leads to a build-up of aberrant, immature myeloid cells in blood and marrow, which disrupts normal hematopoiesis. [ 1–3 ] Although RBP4, AHSG, and LRG are the most promising MDS marker candidates the widespread heterogeneity in MDS has also been demonstrated in proteomic case studies of MDS in progression. [ 4 ] One of the characteristics of MDS was a higher probability of acute myeloid leukemia (AML) transformation. According to the World Health Organization's (WHO) 5th edition classification (WHO 2022), the myeloblast threshold requires ≥20% in both peripheral blood or bone marrow for AML. The International Consensus Classification and WHO 2022 differ in terms of blast threshold. Ten percent or more blasts in the peripheral blood or bone marrow are required by the International Consensus Classification. [ 5 ] About 30% to 40% of patients with MDS have transformation to AML, which is known as "secondary AML to MDS" and is connected to a minimum of 20% myeloblast count. [ 6 , 7 ] Nonetheless, a majority of individuals with myelodysplastic syndromes possess a normal karyotype, and individuals with similar chromosomal abnormalities frequently exhibit different clinical presentations. Recent advancements in next-generation sequencing (NGS) have made it achievable to locate novel genetic abnormalities. A growing variety of genetic abnormalities have been linked to myeloid neoplasm development, progression, and prognosis. [ 8–10 ] Recurrent somatic mutations over a number of genes were found at the time of diagnosis and during leukemic transformation in MDS patients by the use of sequencing techniques. The molecules involved in DNA methylation, chromatin modification, RNA splicing, transcription, signal transduction, cohesin regulation, and DNA repair are among the main targets of mutations in MDS. Genes implicated in chromatin modification (EZH2, ASXL1), DNA methylation (DNMT3A, TET2, and IDH1–2), transcriptional regulation (RUNX1, GATA2, and EVI1), a cohesin complex, and RNA splicing (SF3B1, SRSF2, U2AF1, and ZRSR2) were found to be recurrently mutated. [ 2 , 11–13 ] SF3B1, ASXL1, DNMT3A, SRSF2, RUNX1, TET2, EZH2, U2AF1, IDH1/2, TP53, ETV6, SETBP1, JAK2, CBL, STAG2, ZRSR2, and NRAS were the most often altered genes, while no mutant genes were detected in more than one-third of cases. Adverse clinical aspects, including poor/very poor cytogenetics such as complex karyotypes (TP53), thrombocytopenia (NRAS, RUNX1, and TP53) and enhanced blast proportion (NRAS, RUNX1, and TP53) are linked to several of these gene variants. Despite numerous gene mutations have value for predicting survival and are associated with poor clinical features, they are not included in prognostic scoring systems. In many studies of different cohorts, it has been demonstrated that lower overall survival (OS) can be predicted by mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 in multivariable models adjusted for International Prognostic Scoring System (IPSS) or Revised International Prognostic Scoring System (IPSS-R) risk groups. [ 14 , 15 ] Decreased OS has also been linked to other altered genes, such as U2AF1, SRSF2, KRAS, SETBP1, DNMT3A, CBL, and PRPF8. [ 14–20 ] Even after adjusting for the IPSS-R, better results have been linked to only SF3B1 mutations in some, but not all studies. [ 15 , 21 , 22 ] The goal of our study was to determine the impact of using NGS in clinical practice on the overall survival of MDS patients.

Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms

Impact of TET2, SRSF2, ASXL1 and SETBP1 Mutations on Survival of Patients with Chronic Myelomonocytic Leukemia.

Co-Mutation Landscape and Clinical Significance of RAS Pathway Related Gene Mutations in Patients with Myelodysplastic Syndrome

TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia.

Co-mutation Landscape and Its Prognostic Impact on Newly Diagnosed Adult Patients with NPM1 Mutated De Novo Acute Myeloid Leukemia.

Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes.

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients

Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia

Mutational Landscape of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes in the Context of RUNX1 Mutation.

Clinical and Prognostic Profile of SRSF2 and Related Spliceosome Mutations in Patients with Acute Myeloid Leukemia.

P1.03-35 Analysis of TET2 Gene Aberrations in East Asian Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis

Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study

Spectrum Of Gene Mutations And Clinical Significance In Myeloid Malignancies Patients With Asxl1 Mutations

[Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with FLT3 Mutations]

Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia

Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia

Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience

Clinical Significance of TET2 Mutation in Patients with Myelodysplastic Syndromes